基本信息
浏览量:325
职业迁徙
个人简介
He is funded by the US Department of Defense, PCF/Movember, the NIH, and the American Cancer Society for his work on circulating tumor cell biology and epithelial plasticity. He led the development of enzalutamide and its FDA approval for men with metastatic prostate cancer. He was a Prostate Cancer Foundation, AACR, and ASCO Young Investigator Award recipient. He co-chaired Prostate Cancer Working Group 3, and has been a leading writing member of the NCCN Prostate Cancer Panel since 2012 for national clinical guidelines on the treatment of men with prostate cancer. Dr. Armstrong has developed a number of experimental agents in prostate and renal cell cancer, including AR inhibitors, immunotherapies, mTOR/PI3K inhibitors, and anti-angiogenic agents, and he is heavily involved in the leadership of multiple ongoing phase 1-4 treatment and biomarker trials in men with advanced prostate cancer, including serving as correlative science chair within the NCI ALLIANCE Cooperative Group in the GU Committee. He has authored over 160 peer-reviewed publications, as well as numerous chapters, reviews, and abstracts. He leads a team of over 50 research nurses, coordinators, data managers, regulatory specialists, scientists, and investigators dedicated to discovery science in GU cancers in the laboratory and treatment science in the clinic.
His goals are to develop and provide treatments that prolong and improve quality of the lives of patients with aggressive prostate, kidney, bladder, and testicular cancer. This work involves the direct care of patients in the clinic and clinical research involving the development of new therapies in clinical trials. He devotes over half of my time to understanding how prostate cancer spreads and resists therapies, as well as methods of measuring this biology in patients, which may lead to improved therapies designed to block this process.
There are his reasearches including:
1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition
His goals are to develop and provide treatments that prolong and improve quality of the lives of patients with aggressive prostate, kidney, bladder, and testicular cancer. This work involves the direct care of patients in the clinic and clinical research involving the development of new therapies in clinical trials. He devotes over half of my time to understanding how prostate cancer spreads and resists therapies, as well as methods of measuring this biology in patients, which may lead to improved therapies designed to block this process.
There are his reasearches including:
1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition
研究兴趣
论文共 613 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Investigational New Drugspp.1-2, (2024)
Pedro Barata, Reagan Barnett,Albert Jang, Sree Lanka, Pingfu Fu, Leslie Bucheit,Hani Babiker,Alan Bryce, Haley Meyer, Yujin Choi, Casey Moore,Rohan Garje,
crossref(2024)
Fred Saad,Andrew J. Armstrong,Mototsugu Oya, Karina Vianna,Mustafa Özgüroğlu,Craig Gedye,Gary L. Buchschacher,Ji Youl Lee,Urban Emmenegger,Jiri Navratil,Juan Antonio Virizuela, Anibal Salazar,
JCO precision oncologyno. 8 (2024): e2300567-e2300567
Zeynep B. Zengin,Nicholas C. Henderson,Joseph J. Park,Alicia Ali, Charles Nguyen,Clara Hwang,Pedro C. Barata,Mehmet A. Bilen,Laura Graham, George Mo,Deepak Kilari,Abhishek Tripathi,
Prostate Cancer and Prostatic Diseasespp.1-3, (2024)
CLINICAL CANCER RESEARCHno. 6 (2024): 1152-1159
Mu-En Wang, Wei-Ling Tu,Yi Lu, Jinjin Wu, Alyssa Bawcom,Andrew J. Armstrong,Qianben Wang,Yuzhuo Wang,Jiaoti Huang,Ming Chen
Cancer Researchno. 6_Supplement (2024): 948-948
JU open plusno. 4 (2024)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn